Nicox (ALCOX) Stock Overview
Operates as an ophthalmology company in France and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ALCOX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Nicox S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.41 |
| 52 Week High | €0.65 |
| 52 Week Low | €0.20 |
| Beta | 0.43 |
| 1 Month Change | -16.58% |
| 3 Month Change | 38.33% |
| 1 Year Change | 61.79% |
| 3 Year Change | -30.02% |
| 5 Year Change | -90.58% |
| Change since IPO | -99.59% |
Recent News & Updates
Shareholder Returns
| ALCOX | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | 0% | -11.1% | -0.9% |
| 1Y | 61.8% | 279.0% | -5.9% |
Return vs Industry: ALCOX underperformed the French Biotechs industry which returned 275.2% over the past year.
Return vs Market: ALCOX exceeded the French Market which returned -5.5% over the past year.
Price Volatility
| ALCOX volatility | |
|---|---|
| ALCOX Average Weekly Movement | 10.7% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in FR Market | 10.6% |
| 10% least volatile stocks in FR Market | 2.8% |
Stable Share Price: ALCOX's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: ALCOX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 5 | Gavin Spencer | www.nicox.com |
Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve eye health. The company’s lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial.
Nicox S.A. Fundamentals Summary
| ALCOX fundamental statistics | |
|---|---|
| Market cap | €36.57m |
| Earnings (TTM) | -€27.06m |
| Revenue (TTM) | €3.32m |
Is ALCOX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALCOX income statement (TTM) | |
|---|---|
| Revenue | €3.32m |
| Cost of Revenue | €13.49m |
| Gross Profit | -€10.18m |
| Other Expenses | €16.88m |
| Earnings | -€27.06m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.31 |
| Gross Margin | -306.95% |
| Net Profit Margin | -816.13% |
| Debt/Equity Ratio | -310.4% |
How did ALCOX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/26 10:38 |
| End of Day Share Price | 2026/03/26 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nicox S.A. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Stephanie Lefebvre | Gilbert Dupont |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Mohammad Fazeli | Piper Sandler Companies |